Quick Read – REGN sits 15% below its year-start price despite strong earnings, while MRNA has surged 177% into an August 5 FDA flu vaccine ruling. – VKTX carries 175% analyst upside potential but remains pre-revenue, making its dual GLP-1/GIP Phase 3 obesity trials a binary…
ent for investors. – Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Regeneron didn’t make the cut. Grab the names FREE today
Biotech is setting up as one of the more interesting risk-on trades heading into the back half of 2026. FDA calendars are stacked, obesity Phase 3 readouts are approaching, and after a mixed first half, the sector’s dispersion is wide enough to build a tiered basket. Below are three names structured by risk: a diversified large-cap compounder, a platform story with a near-term regulatory catalyst, and a speculative pipeline play trading near a 52-week high.
Regeneron (REGN): The Safest Tier Regeneron (NASDAQ:REGN) anchors the basket. Shares trade around $687.40 as of July 28, still down 11.45% year to date despite a string of quarterly beats. That disconnect is the setup.